vorinostat has been researched along with T-Cell Lymphoma in 17 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma (CTCL)." | 7.74 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. ( Fantin, VR; Frankel, SR; Gooden, F; Harrington, EA; Hendrickson, RC; Hou, XS; Kadin, ME; Korenchuk, S; Li, L; Loboda, A; Paweletz, CP; Pierce, JW; Randolph, S; Reilly, JF; Richon, VM; Roth, JA; Ware, CM, 2008) |
| " Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease." | 4.88 | HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. ( Khan, O; La Thangue, NB, 2012) |
| " The histone deacetylase (HDAC) inhibitors and the synthetic cytotoxic retinoid fenretinide have achieved durable clinical responses in T-cell lymphomas as single agents, and patients who failed prior HDAC inhibitor treatment have responded to fenretinide." | 4.02 | Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. ( Chen, WH; Hindle, A; Kang, MH; Koneru, B; Makena, MR; Nguyen, TH; Reynolds, CP; Verlekar, DU, 2021) |
| " Fractionation of the crude extract led to the isolation of a new cytotoxin, designated santacruzamate A (1), which has several structural features in common with suberoylanilide hydroxamic acid [(2), SAHA, trade name Vorinostat], a clinically approved histone deacetylase (HDAC) inhibitor used to treat refractory cutaneous T-cell lymphoma." | 3.79 | Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. ( Balunas, MJ; Engene, N; Gerwick, WH; Lopez, DD; McPhail, KL; Ononye, S; Pavlik, CM; Wong, CY, 2013) |
| "Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma (CTCL)." | 3.74 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. ( Fantin, VR; Frankel, SR; Gooden, F; Harrington, EA; Hendrickson, RC; Hou, XS; Kadin, ME; Korenchuk, S; Li, L; Loboda, A; Paweletz, CP; Pierce, JW; Randolph, S; Reilly, JF; Richon, VM; Roth, JA; Ware, CM, 2008) |
| "Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)." | 2.80 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015) |
| "Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies." | 2.46 | The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. ( Hymes, KB, 2010) |
| "SAHA inhibited tumor progression and metastasis in the murine xenograft model." | 1.40 | Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. ( Fujiwara, S; Goshima, F; Imadome, K; Iwata, S; Kanazawa, T; Kimura, H; Murata, T; Nakagawa, H; Siddiquey, MN; Suzuki, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Dehmel, F | 1 |
| Ciossek, T | 1 |
| Maier, T | 1 |
| Weinbrenner, S | 1 |
| Schmidt, B | 1 |
| Zoche, M | 1 |
| Beckers, T | 1 |
| Suzuki, T | 1 |
| Ota, Y | 1 |
| Ri, M | 1 |
| Bando, M | 1 |
| Gotoh, A | 1 |
| Itoh, Y | 1 |
| Tsumoto, H | 1 |
| Tatum, PR | 1 |
| Mizukami, T | 1 |
| Nakagawa, H | 2 |
| Iida, S | 1 |
| Ueda, R | 1 |
| Shirahige, K | 1 |
| Miyata, N | 1 |
| Pavlik, CM | 1 |
| Wong, CY | 1 |
| Ononye, S | 1 |
| Lopez, DD | 1 |
| Engene, N | 1 |
| McPhail, KL | 1 |
| Gerwick, WH | 1 |
| Balunas, MJ | 1 |
| Makena, MR | 1 |
| Nguyen, TH | 1 |
| Koneru, B | 1 |
| Hindle, A | 1 |
| Chen, WH | 1 |
| Verlekar, DU | 1 |
| Kang, MH | 1 |
| Reynolds, CP | 1 |
| Islam, S | 1 |
| Espitia, CM | 1 |
| Persky, DO | 1 |
| Carew, JS | 1 |
| Nawrocki, ST | 1 |
| Kitadate, A | 1 |
| Ikeda, S | 1 |
| Abe, F | 1 |
| Takahashi, N | 1 |
| Shimizu, N | 1 |
| Matsue, K | 1 |
| Tagawa, H | 1 |
| Zhang, Q | 1 |
| Wang, S | 1 |
| Chen, J | 1 |
| Yu, Z | 1 |
| Siddiquey, MN | 1 |
| Iwata, S | 1 |
| Kanazawa, T | 1 |
| Suzuki, M | 1 |
| Imadome, K | 1 |
| Fujiwara, S | 1 |
| Goshima, F | 1 |
| Murata, T | 1 |
| Kimura, H | 1 |
| Nieto, Y | 1 |
| Valdez, BC | 1 |
| Thall, PF | 1 |
| Ahmed, S | 1 |
| Jones, RB | 1 |
| Hosing, C | 1 |
| Popat, U | 1 |
| Shpall, EJ | 1 |
| Qazilbash, M | 1 |
| Gulbis, A | 1 |
| Anderlini, P | 1 |
| Alousi, A | 1 |
| Shah, N | 1 |
| Bashir, Q | 1 |
| Liu, Y | 1 |
| Oki, Y | 1 |
| Hagemeister, F | 1 |
| Fanale, M | 1 |
| Dabaja, B | 1 |
| Pinnix, C | 1 |
| Champlin, R | 1 |
| Andersson, BS | 1 |
| Duvic, M | 1 |
| Klemke, CD | 1 |
| Goerdt, S | 1 |
| Zhang, QL | 1 |
| Wang, L | 1 |
| Zhang, YW | 1 |
| Jiang, XX | 1 |
| Yang, F | 1 |
| Wu, WL | 1 |
| Janin, A | 1 |
| Chen, Z | 1 |
| Shen, ZX | 1 |
| Chen, SJ | 1 |
| Zhao, WL | 1 |
| Huang, WJ | 1 |
| Chen, CC | 1 |
| Chao, SW | 1 |
| Lee, SS | 1 |
| Hsu, FL | 1 |
| Lu, YL | 1 |
| Hung, MF | 1 |
| Chang, CI | 1 |
| Hymes, KB | 1 |
| Khan, O | 1 |
| La Thangue, NB | 1 |
| Smeltzer, JP | 1 |
| Viswanatha, DS | 1 |
| Habermann, TM | 1 |
| Patnaik, MM | 1 |
| Fantin, VR | 1 |
| Loboda, A | 1 |
| Paweletz, CP | 1 |
| Hendrickson, RC | 1 |
| Pierce, JW | 1 |
| Roth, JA | 1 |
| Li, L | 1 |
| Gooden, F | 1 |
| Korenchuk, S | 1 |
| Hou, XS | 1 |
| Harrington, EA | 1 |
| Randolph, S | 1 |
| Reilly, JF | 1 |
| Ware, CM | 1 |
| Kadin, ME | 1 |
| Frankel, SR | 1 |
| Richon, VM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173] | Phase 1 | 78 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma[NCT00091559] | Phase 2 | 74 participants (Actual) | Interventional | 2005-02-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for vorinostat and T-Cell Lymphoma
| Article | Year |
|---|---|
Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cytokines; Depsipeptides; Epigenesis, Gen | 2019 |
Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antige | 2008 |
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Depsipeptides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; | 2010 |
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Topics: Acetylation; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetyla | 2012 |
1 trial available for vorinostat and T-Cell Lymphoma
| Article | Year |
|---|---|
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr | 2015 |
12 other studies available for vorinostat and T-Cell Lymphoma
| Article | Year |
|---|---|
Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
Topics: Carbon; Carbonates; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Histone Deacetylase I | 2007 |
Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Click Chemistry; Histone De | 2012 |
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
Topics: Carbamates; Cyanobacteria; Cytotoxins; Drug Screening Assays, Antitumor; HCT116 Cells; Histone Deace | 2013 |
Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolifer | 2021 |
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.
Topics: Cell Line, Tumor; Histone Deacetylase Inhibitors; Histones; Humans; Lymphoma, T-Cell; Oncolytic Viro | 2020 |
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Bi | 2018 |
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progres | 2014 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2015 |
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase | 2009 |
Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Topics: Binding Sites; Catalytic Domain; Computer Simulation; Coumarins; HeLa Cells; Histone Deacetylase Inh | 2010 |
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Humans; Hydro | 2012 |
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2008 |